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Importance of individual activated protein C cleavage site regions in
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Activated protein C (APC) cleavage of Factor Va (FVa) at residues R506 and R306 correlates with its inactivation.
APC resistance and increased thrombotic risk are due to the mutation R506Q in Factor V (FV). To study the effects
of individual cleavages in FVa by APC and the importance of regions near the cleavage sites, the following
recombinant (r) human FVs were prepared and purified: wild-type, Q306-rFV, Q506-rFV, and Q306Q506-rFV. All had
similar time courses for thrombin activation. Q506-rFVa was cleaved by APC at R306 and was moderately resistant to
APC in plasma-clotting assays and in prothrombinase assays measuring FVa residual activity, in agreement with
studies of purified plasma-derived Q506-FVa. Q306-rFVa was cleaved by APC at R506 and gave a low APC-resistance
ratio similar to Q506-rFVa in clotting assays, whereas unactivated Q306-rFV gave a near-normal APC-resistance
ratio. When FVa residual activity was measured after long exposure to APC, Q306-rFVa was inactivated by only
# 40% under conditions where Q506-rFVa was inactivated . 90%, supporting the hypothesis that efficient
inactivation of normal FVa by APC requires cleavage at R306. In addition, the heavy chain of Q306-rFVa was cleaved
at R506 much more rapidly than activity was lost, suggesting that FVa cleaved at only R506 is partially active. Under
the same conditions, Q306Q506-rFVa lost no activity and was not cleaved by APC. Therefore, cleavage at either R506
or R306 appears essential for significant inactivation of FVa by APC. Modest loss of activity, probably due to
cleavage at R679, was observed for the single site rFVa mutants, as evidenced by a second phase of inactivation.
Q306Q506-rFVa had a low activity-to-antigen ratio of 0.50±0.77, possibly due to abnormal Factor Xa (FXa) binding.
Furthermore, Q306Q506-rFV was very resistant to cleavage and activation by FXa. Q306Q506-rFV appeared to bind
FXa and inhibit FXa's ability to activate normal FV. Thus, APC may downregulate FV/Va partly by impairing FXa-
binding sites upon cleavage at R306 and R506. This study shows that R306 is the most important cleavage site for
normal efficient inactivation of FVa by APC and supports other studies suggesting that regions near R306 and R506
provide FXa-binding sites and that FVa cleaved at only R506 retains partial activity.
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Coagulation Factor Va (FVa) is a cofactor for Factor Xa (FXa)
that increases by <500-fold the kcat for conversion of pro-
thrombin to thrombin in the prothrombinase complex [1±4].
FVa is down-regulated by proteolytic inactivation by activated
protein C (APC) [5±7], and the importance of APC as a negative
regulator of blood coagulation is illustrated by the association of
an increased risk for venous thrombosis with heterozygous
deficiency of protein C, and of potentially fatal purpura
fulminans at birth with homozygous deficiency [8±11].
APC resistance of patient plasma (i.e. the failure of plasma to
show normal prolongation of clotting times with addition of
APC) was recently found to be associated with 20±50% of cases
of venous thrombosis [12±15]. The defect was shown to reside
in the FV gene, and in over 90% of cases was associated with a
G-to-A mutation at nucleotide 1691, resulting in Arg506Gln at
an APC cleavage site in Factor V (FV) [16±19]. This mutation
is found in <5% of the Caucasian population. The phenotype is
variable and often asymptomatic, probably depending on the
presence of additional genetic and/or acquired thrombotic risk
factors [20±23]. Plasma samples from homozygous subjects
exhibit a very pronounced resistance to prolongation of clotting
time by APC and these individuals are at higher risk of venous
thrombosis than heterozygous subjects.
Past studies [24±26] have demonstrated the presence of two
important APC cleavage sites in the heavy chain of FV, one at
arginine 306 and another at arginine 506. Recent studies [27±29]
using plasma-derived normal and Arg506Gln-FVa (Q506-FVa)
demonstrated that Q506-FVa was inactivated . 90% by APC,
although at a rate <8±10-fold more slowly than normal FVa.
The inactivation of Q506-FVa was accompanied by cleavage at
R306. Thus, cleavage at R506 may not result in complete
inactivation of FVa, and functional inactivation of FVa may
require cleavage at R306. The significance of a third APC-
cleavage site at R679 is less clear [25].
In order to clarify the importance of the three heavy-chain
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cleavage sites for APC inactivation of FVa, wild-type recom-
binant human FV molecules were prepared, as well as the
mutants Arg306Gln (Q306-rFV), Arg506Gln-rFV (Q506-rFV)
and a mutant containing both substitutions (Q306Q506-rFV).
Although previous studies with wild-type human and murine
rFV were performed with conditioned media [30±35], the rFVs
were purified for the present studies. The rFVas were compared
with each other and with purified plasma-derived normal FVa
and Q506-FVa as to activity, time course of activation by
thrombin and FXa, proteolytic cleavages by APC, and resistance
to APC in clotting assays and in purified component prothrom-
binase assays measuring FVa residual activity. Insights were
gained concerning the relative importance of the three APC
cleavages in inactivating FVa and possible functions of FVa
regions near APC cleavage sites. Preliminary reports of this
work were presented at the American Society of Hematology
Meeting, December 1996 [35a] and at the XVIth Congress




Unless otherwise specified, protein C [37], plasma-derived FV
[38] and prothrombin [39] were purified and activated as
described previously. Heavy chain of FVa was prepared from
FVa on a Sepharose (Pharmacia, Parsipanny, NJ, USA) column
coupled with 3 mg´mL21 FV anti-(heavy chain) mAb 3B1
(kindly provided by Drs Tilman Hackeng and Bonno Bouma).
FVa light chain and activation peptides were eluted with 5 mm
EDTA, and heavy chain was then eluted with 2 m NaCl and
dialyzed against Hepes-buffered saline (HBS). Antibodies to
FVa heavy chain were raised in rabbits and IgG fraction was
prepared. Rabbit anti-(FV) was obtained from Accurate Chemical
and Scientific (Westbury, NY, USA). Part of the IgG fraction was
biotinylated [40]. Thrombin and FXa were obtained from Enzyme
Research Laboratories (South Bend, IN, USA) and FXa activity
was determined by active-site titration. The mAb to FVa light
chain was obtained from Hematologic Technologies (Burling-
ton, VT, USA).
Construction of FV mutant-expression vectors
Wild-type rFV contained in pBSII has been described pre-
viously [31]. The mutations R506Q and R306Q were introduced
using overlap-extension PCR mutagenesis. For the Q506 mutant,
FV cDNA was used as template and two PCR products were
generated, one that contained sequences spanning residues
1±510 and another that spanned residues 499±536. The 3 0
primer for the N-terminus-coding PCR product and the 5 0
primer for the C-terminus-coding PCR product were comple-
mentary to one another and contained the appropriate mutation
at residue 506 (5 0-CTGGACAGGCAAGGAATACAG-3 0). Puri-
fication of the N-terminal and C-terminal fragments followed by
a joining PCR reaction using the 5 0 primer as the N-terminal
product and the 3 0 primer as the N-terminal PCR product
yielded a ClaI±KpnI fragment that was reintroduced into the FV
cDNA in the vector pBSII. The Q306 mutation was constructed
in a similar manner using the mutagenic primer (5 0-AAA-
GAAAACCCAGAATCTTAAG-3 0). To construct a FV cDNA
that had both the Q506 and Q306 mutations, the strategy described
for the construction of Q506 was used except that the template
used had a mutation coding for Q306. Mutant cDNAs were
subsequently subcloned from pBSII into the expression vector
pED [41] and used for DNA sequence analysis as well as
functional analysis.
Expression and preliminary analysis of rFV molecules
Wild-type and mutant rFV expression plasmids were transfected
into COS-1 cells [30]. At 48-h post-transfection the cells were
metabolically labeled using 35S-methionine/cysteine (Promix,
Amersham, UK) and immunoprecipitated with FV-specific anti-
serum (Dako Corp., Carpinteria, CA, USA) [31]. rFVs were
subjected to SDS/PAGE before and after activation with 10 nm
thrombin [31] to confirm that the characteristic heavy chains,
light chains and activation polypeptides were released.
Functional analysis of rFV in culture supernatant
Conditioned media were collected for 24 h using serum-free
OPTI-MEM (Gibco, MD, USA) at 48-h post-transfection of
COS-1 cells. rFV activity in the media was measured in a FV
clotting assay using FV-deficient plasma [31,42]. One hundred
microliters of diluted media were incubated with 100 mL FV-
deficient plasma (George King Biomedical Inc., Overland Park,
KS, USA) at 37 8C for 1 min. Thromboplastin (100 mL, Sigma
Corp., St Louis, MO, USA) was added and incubated for 3 min.
After the addition of 100 mL of 25 mm CaCl2 clotting time was
measured using an Electra 750 coagulometer. rFV activity was
calculated using a standard curve consisting of dilutions of
pooled normal human plasma (NHP) (George King Biomedical
Inc., 1 U´mL21).
Purification of rFV
The culture supernatant of each rFV (250±400 mL) was thawed
at 37 8C, placed on ice and treated with 1 mm PhCH2SO2F
(Sigma), 10 mm benzamidine (Sigma) and 10 nm Phe-Pro-Arg
chloromethylketone (PPACK) (Chemica Alta, Edmonton, Alberta,
Canada). The mixture was centrifuged for 15 min at 10 000 g and
4 8C, and the supernatant was loaded at 4 8C onto a 2-mL column
of CNBr±Sepharose (Pharmacia) coupled with 2 mg of anti-(FV
heavy chain) mAb AHV 5101 (Hematologic Technologies) at a
flow rate of 0.4 mL´min21. The column was then washed with
HBS containing 5 mm CaCl2, 2 mm benzamidine and 5 nm
PPACK, and then with the same buffer containing 0.3 m NaCl
until less than 0.5 mg´mL21 rFV activity was detected in the
eluate. The column was taken to room temperature, washed at
0.1 mL´min21 with 50 mL of the same buffer containing a final
concentration of 0.5 m NaCl and then with the same buffer
containing a final concentration of 1.8 m NaCl until all detect-
able rFV activity was eluted. Fractions were chilled to 5 8C and
analyzed for SDS/PAGE profile, FV activity and FV antigen.
Pooled fractions were treated with 1 mm diisopropyl fluorophos-
phate (Sigma), concentrated, stabilized with 0.2% BSA, dia-
lyzed against HBS-5 mm CaCl2 and frozen in aliquots at 280 8C.
Activation of rFVs
rFVas were prepared by activation of each rFV with 10 nm
thrombin in 20% glycerol for 20 min at 37 8C. Thrombin was
neutralized with a 1.2-fold molar excess of hirudin (Sigma) and
FVa aliquots were frozen. In some experiments, time courses of
activation of each rFV were performed, using 1 nm thrombin or
1 nm FXa with 10 mm phospholipid vesicles containing 20%
bovine brain phosphatidyl serine and 80% bovine liver phos-
phatidyl choline (Sigma). Aliquots were tested over time for
rFVa activity in prothrombinase assays.
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Prothrombinase assays
rFV/Va activity was measured by prothrombinase assays [40,43]
with 20 pm FV, FVa, rFV or rFVa, 1 nm FXa, 25 mm
phospholipid vesicles, 0.3 mm prothrombin, HBS, 0.5% BSA
and 5 mm CaCl2, unless otherwise specified. In this assay, FV
became fully activated in , 20 s following the addition of
prothrombin to start the reaction. Aliquots were removed from
the reaction mixture over time and quenched in buffer contain-
ing 10 mm EDTA. The rate of thrombin formation was assessed
with thrombin substrate CBS 34.47 (American Bioproducts,
Parsippany, NJ, USA) using the Kineticalc program on a Biotek
microtiter plate reader (Winooski, VT, USA). To monitor the
time course of activation of rFVs by thrombin or FXa, only
40 pm FXa and 10 mm phospholipid vesicles (final concentra-
tions) were employed in the assays to prevent further FV acti-
vation during measurement [32]. A standard of stable, purified
plasma-derived FV was prepared, frozen in aliquots and checked
periodically for activity against FV in NHP. The concentration
of FV in the standard was determined in the ELISA described
below and it had the same activity as plasma FV when activated
with thrombin.
For some experiments, rFVa was preincubated for various
times with APC in the presence of 25 mm phospholipids prior to
assay of rFVa residual activity in prothrombinase assays.
Controls showed that the same results were obtained whether
or not APC was inactivated with 100 mm p-amidino-phenyl-
methanesulfonyl fluoride (pAPMSF) (Chemicon, Carpenteria,
CA, USA) for 20 min at the end of the preincubation time prior
to assay for rFVa activity. Therefore, inactivation of rFVa
during the time required for measurement of residual rFVa
activity (2 min) in the presence of protective FXa was negli-
gible. Controls showed that pAPMSF did inactivate APC and
did not affect the prothrombinase assays after 20 min of decay.
APC-resistance assays
Activated partial thromboplastin time (APTT) was determined
for each rFV or rFVa in FV-depleted plasma in the presence or
absence of 1 mg´mL21 APC [28]. The ratio of the clotting time
in the presence of APC to that in the absence of APC (APC-
resistance ratio) was determined and compared with that of
normal and homozygous Q506-FV plasma and purified plasma-
derived FV, Q506-FV, FVa and Q506-FVa.
SDS/PAGE and immunoblot analysis
SDS/PAGE was performed on 4±15% minigels. Gels were
silver stained or transferred to Immobilon membranes (Milli-
pore, Bedford, MA, USA) and subjected to immunoblotting
[28]. Incubation mixtures contained 2.4 nm FVa or rFVa, 25 mm
phospholipids and 400 pm APC unless otherwise stated. Ali-
quots of the incubation mixtures containing 32 ng FVa or rFVa
were taken over time and boiled for 2 min with SDS prior to
electrophoresis and immunoblotting. At the same time, aliquots
were taken for measurement of FVa residual activity. Immuno-
blots were developed with rabbit anti-(FV heavy chain IgG)
(10 mg´mL21) combined with anti-(FV heavy chain) mAb VE
(Enzyme Research Laboratories) at 2 mg´mL21, followed by
biotin-donkey anti-(rabbit IgG) and biotin-goat anti-(mouse
IgG) (Pierce, Rockford, IL, USA) each diluted 1 : 1000. Further
development employed streptavidin±alkaline phosphatase (Pierce)
1 : 500 and color development with BCIP/NBT substrate (Bio-
Rad, Hercules, CA, USA). In some experiments, 125I-secondary
antibodies were used instead of the biotin±streptavidin system.
These immunoblots were exposed to a phosphoimaging screen
for 24 h. The screen was read on a Phosphoimager (Molecular
Dynamics, Sunnyvale, CA, USA) and bands were quantitated.
Ligand-binding analysis
Binding of FXa to immobilized FVs was detected using the
biotin±streptavidin system described above. The detecting anti-
bodies were mAb anti-(FX) (Biodesign, Kennebunk, ME, USA)
followed by biotin-goat anti-(mouse IgG) (Pierce).
FV antigen detection
A variation of an ELISA method for the determination of FV
antigen was used [28]. Microtiter plates were coated with
5 mg´mL21 rabbit anti-(FV IgG). Wells were blocked and
samples or standards consisting of dilutions of NHP (beginning
at 1 : 100) were prepared in 0.5% BSA/HBS and incubated in
the wells for 1 h at 23 8C and 16 h at 4 8C. Bound FV was
detected with biotin-rabbit anti-(FV IgG) followed by strepta-
vidin±alkaline phosphatase and p-nitrophenyl phosphatase
substrate. Absorbance at 405 nm was taken, standard curves
were constructed and unknowns were calculated. Standard
curves for dilutions of NHP were parallel to those for dilutions
of purified FV.
RESULTS
Construction and expression of APC-cleavage-site mutants
of FV
To directly assess the significance of each of the APC-cleavage
sites in FV, mutant rFVs were generated containing an Arg-to-
Gln substitution at residues 306, 506 or both. FV procoagulant
activity in the conditioned media ranged from 2.0 to 2.4 mg´mL21
from cells transfected with the wild-type and mutant FV
expression plasmids but not from transfected cells that did not
receive DNA.
rFVs were metabolically labeled with [35S]-methionine/
cysteine and, after a 4-h chase, the media were harvested for
immunoprecipitation of rFV. A 330-kDa band observed by SDS/
PAGE was immunoprecipitated from cells expressing rFV,
Q506-rFV, Q306-rFV and Q306Q506-rFV but not from mock-
transfected cells (Fig. 1). Similar quantities of secreted proteins
were detected for the wild-type and each mutant, indicating that
the mutations did not significantly interfere with their folding to
impair their secretion. The apparent molecular mass of the rFV
agrees with previous reports for rFV [44] and for plasma-
derived FV. When immunoprecipitated rFVs were activated
with thrombin and then resolved by SDS/PAGE, the wild-type
and mutant molecules yielded the characteristic 150-kDa acti-
vation peptide, 102-kDa heavy chain and the 74-kDa light chain
(Fig. 1) expected for FV.
Purification of wild-type and mutant rFV
rFV activity and antigen eluted from the mAb anti-(FV) Sepha-
rose column with similar patterns for each rFV. Recovery was
100±200 mg rFV from 200 to 400 mL of culture supernatants
that contained 400±800 mg rFV. Approximately half of each
rFV was subsequently lost during concentration and dialysis.
Each rFV was pooled in two parts that contained the ascending
and descending limbs (pools I and II) of the rFV peaks.
SDS/PAGE analysis showed that the ascending limb con-
tained visible contaminants, while the descending limb appeared
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. 90% pure, yet no functional differences were detected in the
rFV in the respective ascending and descending limbs of the rFV
peaks. Figure 2A shows a silver-stained gel of the nonreduced
descending limb pools of each rFV and Fig. 2B shows a wild-
type rFV preparation, reduced and nonreduced. The majority of
rFV was single chain migrating at 330 kDa. Part of the rFV was
of lower apparent molecular mass, <190 kDa, possibly due to
proteolytic cleavage near the middle of the B domain between
the heavy and light chain regions, yielding fragments of
<150 kDa and 190 kDa, possibly representing residues
1±1018 and 1019±2196 as reported previously [32, 45].
Ratio of activity to antigen for rFV molecules
The activity and antigen values for the ascending and descend-
ing limb pools (I and II) of each rFV were determined
immediately after purification, and then from aliquots frozen
and assayed at later times. For the immediate activity measure-
ments, saturating FXa (1 nm) and phospholipids (25 mm) were
used in a standard prothrombinase assay. For the later activity
measurements, a time course for activation by thrombin was
performed and the maximum activity obtained was recorded, as
determined in a prothrombinase assay with 40 pm FXa and
10 mm phospholipids. In either case (Table 1), the wild-type and
Q306-rFVa expressed activity-to-antigen ratios near 1 and near
that of plasma-derived FVa. However, Q506-rFVa expressed
ratios of activity to antigen of $ 1.9, while two preparations of
Q306Q506-rFVa expressed ratios of 0.50 (Table 1) and 0.77 (not
shown). The latter finding suggests that mutations at both 306
and 506 may synergistically affect the ability of FVa to bind
FXa and/or prothrombin, and thus may impair FVa activity.
Immunoblotting analysis for heavy-chain epitopes of Q306Q506-
rFVa showed that all single chain had been converted to heavy
chain by thrombin (Fig. 6), even though its activity-to-antigen
ratio was somewhat low. Similar results, as shown in Table 1,
were obtained for a second preparation of each rFV.
We questioned whether the finding of a high activity-to-
antigen ratio for Q506-rFV might be observed for human
individuals with plasma Q506-FV. We examined the activity-
to-antigen ratio of Q506-FV in the plasma of seven homozygous
individuals, compared with FV in NHP. Q506-FV activity in
homozygous plasma was evaluated in prothrombinase assays as
Fig. 1. SDS/PAGE analysis of 35S-labeled recombinant FV molecules in
culture supernatant. Metabolically labeled rFV was immunoprecipitated
from conditioned medium as described above. Lanes 1±4 contained
untreated rFVs, while rFVs in lanes 5±8 were activated with thrombin.
Lanes 1 and 5, wild-type rFV; lanes 2 and 6, Q506-rFV; lanes 3 and 7, Q306-
rFV; lanes 4 and 8, Q306Q506-rFV. The positions of molecular mass markers
are given in the right margin.
Fig. 2. SDS/PAGE of purified rFactor V molecules. (A) SDS/PAGE and
silver stain of a nonreduced preparation of each rFV. (B) SDS/PAGE and
silver stain of plasma-derived FV and wild-type rFV, reduced with
dithiothreitol (R) and nonreduced (NR). The positions of molecular weight
standards (S) are indicated on the left margins. n indicates normal plasma-
derived FV. Q506 0 indicates plasma-derived Q506-FV.







Pool I 1.2 0.9
Pool II 1.0 1.0
Q506
Pool I 3.4 2.9
Pool II 1.9 2.6
Q306
Pool I 0.9 1.0
Pool II 1.0 1.0
Q306Q506
Pool I 0.4 0.5
Pool II 0.6 0.5
Peak tube 0.5 0.4
aIn the first Activity/Antigen column, these parameters were determined
immediately after purification and concentration of FVs. A standard pro-
thrombinase assay was used with 1 nm FXa and an ELISA as described
above. The peak tube during purification of Q306Q506-rFV by immunoaffin-
ity chromatography was retained in its original tube without pooling,
dialysis, or concentration.bIn the second Activity/Antigen column, values
were determined in aliquots of rFV frozen for 1±5 months. Activity was
taken as the maximal activity obtained over time during activation with 2 nm
thrombin as determined in a prothrombinase assay using 40 pm FXa as
described above. Values were the average of at least three different
determinations on different dates.
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described above for NHP and FVs. Q506-FV plasma from one
individual prepared on several different dates had near-normal
FVa activity, but lower than normal antigen, so that the activity-
to-antigen ratios were 2.1, 1.6 and 1.3, respectively. However,
six unrelated subjects homozygous for Q506-rFV did not have a
FV activity-to-antigen ratio greater than 1.1, and one normal
sibling of the first individual had an activity-to-antigen ratio of
1.4. Therefore, the high activity-to-antigen ratio for Q506-rFVa
and one homozygous individual with Q506-FV was probably not
directly related to this mutation and likely represents variability
in human subjects or cultured cells that synthesize FV, possibly
due to post-translational modifications.
FXa activation, and not thrombin activation, is defective in
the double mutant Q306Q506, but not in either single mutant
Time courses were examined for activation of plasma-derived
FV and each preparation of rFV by 1 nm thrombin, using
400 pm of each rFV as determined by antigen level. When
subsequently assayed in prothrombinase assays, FV in NHP,
purified plasma-derived FV, wild-type and various mutant rFVs
had reasonably similar time courses for activation by thrombin
(Fig. 3, left panel). A rapid phase of activation was observed in
the first 2 min, followed by modest increases in activity up to
10 min. However, as indicated in Table 1 and in data not shown,
three independent preparations of Q506-rFVa had approximately
twofold the maximal activity of normal plasma-derived and
wild-type rFVa, while two preparations of Q306Q506-rFV had
50±77% the maximal activity of normal plasma-derived and
wild-type rFVa. This was true for both the ascending and
descending limb pools of each type of rFV.
Time courses for FXa activation were also examined for each
pool of each rFV, using 1 nm FV, 1 nm FXa and 10 mm phos-
pholipids (Fig. 3, right panel). For plasma-derived FV, wild-
type rFV, Q306-rFV and Q506-rFV, the time courses of activation
by FXa were slightly more rapid but the maximal FVa activities
achieved were reasonably similar to those seen for thrombin
activation. However, Q306Q506-rFV was very resistant to acti-
vation by FXa and activity values did not increase above those
shown in Fig. 3 during 40 min of activation.
Immunoblots such as those shown in Fig. 4 revealed that very
little heavy chain was generated from Q306Q506-rFV during
40 min of FXa activation, although all Q306Q506-rFV single
chain was fully converted to heavy chains (and light chains not
shown) during 5 min of thrombin activation. Other FVs were
mostly converted to heavy and light chains by FXa activation
within 5±15 min (Fig. 4). A second preparation of Q306Q506-
rFV and unpurified Q306Q506-rFV from conditioned medium
were also resistant to FXa activation (not shown). Figure 4 also
illustrates that the antibodies used for immunoblotting recognize
heavy chain . B domain cleaved FV (150 kDa) . single chain
FV. This was not due to a difference in transfer efficiencies,
since 125I-labeled FV and FVa had similar transfer efficiencies
under the conditions used. The 150-kDa fragment was only
Fig. 3. Time course for activation of FV molecules. FVs (1 nm) were incubated with 1 nm thrombin (FIIa) (left panel) or 1 nm FXa and 10 mm phospholipids
(right panel). At various times, aliquots were diluted for assay of FVa activity in prothrombinase assays using 40 pm final FXa. 100% activity was defined as the
maximum activity exhibited by normal plasma-derived FV (nFV). No further increase in activity was observed up to 40 min for any of the activated FVs.
Fig. 4. Immunoblot of FV molecules activated
with FXa. Aliquots from incubation mixtures as
in Fig. 3 were withdrawn at various times as
indicated. Aliquots were boiled with SDS and
subjected to immunoblotting for FVa heavy-chain
epitopes. The positions of single-chain FV, heavy
chain and FV cleaved at or near residue 1018 in
the B domain are noted.
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faintly visible in silver-stained gels (Fig. 2) and by analysis of
immunoprecipitated 35S-labeled protein (Fig. 1). However, on
immunoblots it appeared intense compared with single chain FV
and disproportional to its true mass.
Q306Q506-rFV inhibits FXa's ability to activate normal FV
The mechanism of poor activation of Q306Q506-rFV by FXa was
explored further. The slow generation of the heavy chain of
Q306Q506-rFV by FXa (Fig. 4) could be due to poor binding of
the unactivated double mutant to FXa, or alternately, to binding
in a nonproductive manner. In the latter case, FXa would not
cleave Q306Q506-rFV and therefore might remain bound and
inhibited in its ability to cleave and activate other FVs. To test
these possibilities, FXa was preincubated alone or with various
FVs. After maximal FVa activity was generated, the FXa
mixtures were supplemented with fresh plasma-derived normal
(n) FV. In Figure 5, left panel, we show that FXa that had been
preincubated with Q306Q506-rFV was inhibited in its ability to
generate activity from freshly added nFV, while FXa that was
preincubated alone or with nFV or wild-type FV was not
inhibited. This suggests that some of the Q306Q506-rFV remained
bound to FXa in a nonproductive manner. Indeed, in the ligand
blot in Fig. 5, top panel, we show that FXa incubated with FVs
spotted on nitrocellulose paper remained bound to Q306Q506-rFV
to a far greater extent than to other FVs.
Q306 and Q506 FV and FVa are both partially resistant to APC
as measured in APTT assays
Clinically, APC resistance is defined in terms of APC-resistance
ratios in APTT-clotting assays, where the APC-resistance ratio
is the ratio of the clotting time in the presence of APC divided
by the clotting time in the absence of APC. Therefore, the APC-
resistance ratio was determined for each rFV and rFVa and
compared with the ratios for purified plasma-derived FV and Va
and for purified Q506-FV and Va from an individual homo-
zygous for the Arg506Gln mutation. Each test sample was
diluted into FV-deficient plasma for testing. As seen in Fig. 6,
FV in NHP, purified FV and Va, and wild-type rFV and Va all
had mean APC-resistance ratios $ 2.5. Q506-rFV and Va and
Q306-rFVa had mean APC-resistance ratios of <1.3±1.6, similar
to the APC ratio for plasma-derived Q506-rFV. Q306-rFV had an
intermediate mean APC-resistance ratio of 2.1. Q506Q306-rFV
and its activated form were completely APC resistant with ratios
close to 1.0.
In prothrombinase assays, the order of increasing resistance
to APC inactivation is wild-type-, Q506-, Q306-, and
Q306Q506-rFVa
Figure 7 illustrates the time courses for inactivation of 80 pm
(panel A) or 2.4 nm (panel B) plasma-derived and rFVas by
400 pm APC, where residual FVa activity was measured in
prothrombinase assays with limiting FVa. For each type of FVa,
the symbols represent the averaged data from two to five
experiments. FVa activity was compared with controls with no
APC, where activity varied no more than 10% during a 110-min
incubation.
The averaged data for plasma-derived FVa and wild-type
rFVa were best fit by a biphasic least-squares analysis of FVa
activity vs. time, resulting from cleavages at R506 and R306, as
seen below using immunoblotting analysis of samples taken
simultaneously from experiments in Fig. 7B. Plasma-derived
nFVa and wild-type rFVa (80 pm±3 nm) were inactivated at
rates (in percentage inactivation/time) dependent on the dose of
APC from 33 pm to 2 nm. Wild-type rFVa was more slowly
inactivated than plasma-derived FVa at low dose APC (33 pm,
data not shown).
Q506-rFVa was inactivated by 400 pm APC more slowly than
plasma-derived or wild-type FVa (Fig. 7), with an initial rate of
inactivation at least three times slower than that of nFVa, similar
to results for purified plasma-derived Q506-FVa [28]. Q506-rFVa
was inactivated at essentially the same rate as plasma-derived
Q506-FVa, and the initial rate of inactivation of each was seven
times slower than that of plasma-derived FVa at 33 pm APC
(data not shown). The time course data for Q506-rFVa were best
fit by a two-phase calculation, attributable to cleavage at R306,
possibly followed by R679. In panel B, the second phase might
Fig. 5. Inhibition of FXas ability to activate normal FV in the presence
of Q306Q506-rFV. (top) FXa (730 pm final) and 10 mm phospholipid vesicles
were preincubated for 20 min in duplicate with 545 pm of normal plasma-
derived (n) FV (O), Q306Q506-rFV (+), wild-type rFV (K) or buffer alone
(W). After maximal activation of FVs was achieved (as established by assay
of FVa activity), fresh nFV (432 pm) was added to one aliquot of each
incubation mixture (t = 0 on the x-axis). Subaliquots were then taken of all
mixtures at times indicated and diluted into assay mixtures for FVa activity
as described, at 40 pm final FXa. FVa activity in the samples without fresh
nFV added was subtracted from the corresponding sample with fresh nFV
added to determine nFVa activity generated from the freshly added nFV.
nFVa activity was expressed as a percentage of the expected activity
generated. Generation of nFVa activity from the freshly added nFV by FXa
was inhibited by the presence of Q306Q506-rFV/Va, but not by nFV/Va or
wild-type rFV/Va. (bottom) Ligand binding of FXa with various FVs. FVs as
indicated were spotted on nitrocellulose paper and blocked. The paper was
incubated with 40 nm FXa, 2 mm CaCl2 and 5 mm phospholipid vesicles.
After washing, bound FXa was detected as described. Significantly more
FXa remained bound to Q306Q506-rFV than to other FVs. Controls with no
FXa had negligible signals (not shown).
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possibly be distorted by a type of product inhibition that has
been reported due to FVa light-chain interaction with APC at
high concentrations of FVa up to 200 nm [46]. This effect
should be small at 80 pm FVa as used in Fig. 7, panel A, since
the Kd for APC interaction with FVa light chain was reported as
7 nm.
Q306-rFVa was very resistant to inactivation (Fig. 7), and
Q306-rFVa activity almost reached a plateau at $ 60% during
the 1-h time course. This suggests that cleavage by APC at R306
in nFVa is necessary for efficient inactivation, consistent with
previous reports [27±29]. Cleavage at R506, and perhaps also at
R679, would appear to be responsible for a maximum of 40%
loss of activity in 1 h in nFVa. Thus, the concept of a partially
active form of FVa, cleaved at R506, appears tenable.
The double mutant Q306Q506-rFVa was almost totally resis-
tant (^ 10%) to inactivation by APC under all conditions tested
(Fig. 7). This suggests that cleavage at other sites, such as R679,
either does not occur in this mutant or contributes little to its loss
of activity. Thus, cleavage at either R306 or at R506 is necessary
for any significant loss of FVa activity. However, a second
Fig. 6. APC-resistance ratio of FV and FVa
molecules based on APTT assays. Each type of
FV or its thrombin-activated form was added to
FV-deficient plasma and analyzed ^ APC in an
APTT assay. The ratio of clotting time with APC
to the clotting time without APC was calculated in
each case. Purified FV or FV in normal plasma
was used at a final concentration of 1 nm, while
FVas were used at 40 pm final. Data are from
several different days.
Fig. 7. APC inactivation of FVa molecules at two concentrations of FVa. (A) Thrombin activated FVas (80 pm) were incubated in separate wells of a
polypropylene v-well plate with 20 mm phospholipids. At various times from 0 to 58 min, APC was added to selected wells to 400 pm. At the end of 60 min, the
mixtures were assayed for residual FVa activity (compared with controls without APC) in prothrombinase assays as described above. (B) Incubation mixtures
contained 2.4 nm FVa, 400 pm APC and 20 mm phospholipids. Aliquots were removed over time and assayed for residual FVa activity in prothrombinase assays
at the same time that samples were taken for immunoblot analysis (shown in Fig. 8). Controls without APC remained constant in activity (^ 10%) over the time
course of the experiment.
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phase of inactivation was detected in the case of Q306-rFVa and
Q506-rFVa, suggesting that cleavage at R679 may occur in these
single-site mutants and make a small contribution to their loss of
activity.
In comparing results for 80 pm vs. 2.4 nm FVas in Fig. 7A
and Fig. 7B, data were qualitatively similar, with somewhat
slower rates of inactivation at 2.4 nm FVas than at 80 pm FVas.
Thus, similar inactivation data as described above were obtained
at very different FVa concentrations, and also under conditions
where APC or FVa was in excess. Data for inactivation of FVa
and rFVas at a low concentration of 33 pm APC were subjected
to least-squares analysis using a biphasic fit according to Rosing
et al. [26, 29]. The Rosing laboratory concluded that inactiva-
tion of FVa is first order in both APC and FVa up to a
concentration of 5 nm FVa, allowing the calculation of first-
order rate constants [29]. In our experiments, the respective
mean rate constants for k506 and k306 were determined to be 55
and 9.4 (£ 106 m21´s21). The k506 was 138 for normal FVa and
41 for wild-type rFVa and Q306-rFVa, accounting for the slower
rate of inactivation of the wild-type rFVa as compared with
plasma-derived FVa at low APC concentration. If the second
phase of inactivation in the single-site mutants was due to R679
cleavage, the k679 was 0.6 £ 106 m21´s21. The k306 values for
inactivation of plasma-derived FVa, wild-type and Q506-rFVa
were similar in our experiments, although cleavage at R506 was
reported to provide a 1.4 to 1.7-fold enhancement of cleavage at
R306 [29, 33].
Immunoblot analysis correlates APC cleavages of mutant
rFVa molecules with their resistance to inactivation
Time-dependent APC-cleavage patterns of the heavy chains of
plasma-derived FVa and rFVas were evaluated by immunoblot-
ting (Fig. 8A±D) simultaneously as samples were taken for the
activity measurements in Fig. 7B. The identity of heavy-chain
fragments as indicated was established previously by N-terminal
amino acid sequencing [25, 28], except the fragment tentatively
labeled 680±709. This fragment was recognized by a mAb
whose epitope maps to the C-terminus of the heavy chain,
residues 683±709. We were unable to obtain enough material
for sequencing and confirmation of the identity of this fragment.
For plasma-derived FVa and wild-type rFVa (Fig. 8A, B), the
earliest heavy-chain fragments observed were those at 78 kDa
(residues 1±506) and 28 kDa (residues 507±709), correspond-
ing to cleavage at R506 (Fig. 8). The intensity of the 1±506
fragment was at a maximum within 1 min, and disappeared after
5 min. A band at 44 kDa (residues 1±306) increased in intensity
up to about 10 min, corresponding to cleavage at R306. This
cleavage would be predicted to form an additional fragment of
approximately 28 kDa, corresponding to residues 307±506, but
that band was not efficiently recognized by our antibodies and a
doublet near 28 kDa was barely visible in some lanes of some
blots. The initial 28 kDa fragment corresponding to residues
507±709 diminished after 20 min in association with the
appearance of an additional faint band of , 25 kDa (not seen
on these blots), most likely corresponding to cleavage at R679.
The latter fragment of 25 kDa corresponding to residues 507±679
was not recognized by the anti-(heavy chain) mAb used in the
detection mixture and was only weakly recognized by the
polyclonal antibodies in the detection mixture. In some cases a
low molecular mass fragment (, 14 kDa) was also observed at
< 20 min (Fig. 8A, C, right panels). This fragment probably
represents residues 680±709 due to cleavage at R679, based on
its recognition by a particular mAb as discussed above.
The time-dependent APC-cleavage patterns of Q306-rFVa
heavy chain revealed only fragments of 78 kDa, 28 kDa
(Fig. 8C) and 25 kDa (not visible in this figure), corresponding
to cleavages at R506 followed by R679. On many blots a transient
fragment was observed of low molecular mass (, 14 kDa) that
probably represents residues 680±709, due to cleavage at R679
(Fig. 8C, right and left panels). No fragments were detected that
would result from cleavage at or near residue 306.
The APC-cleavage pattern of Q506-rFVa revealed only frag-
ments of 44 kDa (residues 1±306) and 58 kDa (residues 307±
709), corresponding to cleavage at R306 (Fig. 8D) A diminution
of the 58-kDa band (307±709) after 20 min suggested that
cleavage at R679 may have occurred in concert with the second
phase of inactivation in Fig. 7. The appearance of a 44-kDa
Fig. 8. (A±D) Immunoblots for heavy chains of FVa molecules incubated
with APC. Aliquots of incubation mixtures in Fig. 7(B) were boiled with
SDS and subjected to immunoblotting for heavy-chain epitopes. The
positions of molecular weight standards (S) are shown in the margins, as
well as the location of various FVa heavy chain fragments. At the right side
of B and C, a transient fragment of , 14 kDa is noted that could be due to
cleavage at R679 to produce the fragment 680±709, but this remains to be
verified by sequencing.
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fragment in the first lane, without APC, is likely due to spill-
over from the next lane, as this fragment was not observed on
several other blots of Q506-rFVa, even after 110 min of incu-
bation in the absence of APC.
The Q306Q506-rFVa heavy chain appeared completely resis-
tant to APC because no change in the immunoblot pattern of its
heavy chain was seen with or without APC incubation for
60 min (Fig. 8C), consistent with functional data. Either the
double mutant was not cleaved by APC at R679, or the cleavage
was not detected and did not measurably affect the molecule's
activity (Fig. 7).
Quantitation of heavy-chain fragments during inactivation of
Q306-rFVa
Selected immunoblots of Q306-rFVa inactivation time courses
were subjected to phosphoimaging. Under the conditions used,
the signal for heavy chain was proportional to the mass of heavy
chain. In Fig. 9, bands from an immunoblot of a time course for
inactivation of Q306-rFVa were quantitated relative to the inten-
sity of the heavy chain in the absence of APC (assigned 100%).
There was a rapid cleavage at R506 in the first minute of incu-
bation, producing the fragments 1±506 and 507±709 (Figs 8C
and 9). The heavy-chain band decreased to 62% of its original
intensity in 1 min, whereas activity only decreased to 90% of its
original value in 1 min. The great disparity between activity and
amount of heavy chain lost during 40 min of incubation sup-
ports the concept that FVa cleaved at only R506 retains partial
activity, as suggested by others [24, 29]. It was reported that
APC cleavage at the three equivalent Arg residues in bovine
FVa heavy chain results in dissociation of the A2 domain,
whereas cleavage at only the last two sites (R505 and R662)
results in molecules that are mostly noncovalently associated
[46].
While fragment 1±506 remained relatively constant in inten-
sity during 1±40 min of incubation of Q306-rFVa with APC,
fragment 507±709 diminished significantly by 10±40 min
(Fig. 9). This can also be seen visually in Fig. 8A±C. Thus,
fragment 507±709 is cleaved, possibly at R679. This suggests
that the second, slow phase of inactivation of Q306-rFVa and
Q506-rFVa (Fig. 7) may be due to cleavage at R679, leading to
modest additional loss of activity.
DISCUSSION
This is the first report of studies using purified rFVs. Wild-type
rFVa had similar activity and behaved in a manner very similar
to plasma-derived FVa with respect to activation by thrombin or
FXa and inactivation by APC. In agreement with previous
studies of plasma-derived FVa by Kalafatis et al. [25], there was
preference in both wild-type rFVa and plasma-derived FVa for
an initial APC cleavage at R506, followed by cleavage at R306.
Visual inspection of the wild-type and normal FVa inactivation
time course patterns and polypeptide patterns suggested a third
time-dependent step of inactivation which could involve other
cleavages such as cleavage at R679. The immunoblot fragments
were consistent with a slow cleavage at or near R679.
Wild-type rFVa was inactivated somewhat more slowly at
low doses of APC, as also observed recently by Egan et al. [33].
The reason for the slower cleavage at R506 in the rFVas
compared with plasma-derived FVa could not be determined.
A higher degree of glycosylation of heavy chain and light chains
of FVa can reduce sensitivity to APC [47±49]. However, by
immunoblot analysis for light-chain and heavy-chain epitopes it
did not appear that either the light chains or the heavy chains
were more heavily glycosylated than those of plasma-derived
FVa. When wild-type and plasma-derived FVs were treated with
N-glycanase and sialidase [47], they each became more sen-
sitive to APC, but treated wild-type rFV was still somewhat less
sensitive to APC than treated plasma-derived FVa. rFVs did not
react significantly differently with anti-(phosphotyrosine) or
anti-(phosphoserine) than did plasma-derived FV, so a differ-
ence in phosphorylation was not demonstrated. It is possible that
the degree of sulfation or some other post-translational modi-
fication varied. Plasma-derived FV can be heterogeneous with
respect to phosphorylation, sulfation and glycosylation [47,50,51].
The susceptibility of the mutant Q506-rFVa to APC inactiva-
tion was essentially the same as that of Q506-FVa purified from
the plasma of homozygous APC-resistant patients. Q506-rFVa
was modestly resistant to APC in clotting assays, and in purified
component reaction mixtures, the initial rate of its inactivation
by 33 pm APC was approximately seven times slower than that
of normal FVa. These results for the recombinant variant, Q506-
rFVa, indicate that APC resistance in patients can be explained
by the presence of Q506-FV alone. Q506-rFVa could be . 90%
inactivated, although more slowly than normal FVa. This
observation strengthens the hypothesis [25, 27±29] that efficient
inactivation of FVa requires cleavage at R306, and accordingly,
proteolytic fragments due to cleavage at R306 in Q506-rFVa were
observed. Mutation at 506 does not appear to substantially affect
cleavage at R306, as judged by comparing the rates of formation
Fig. 9. Quantitation of heavy chain and heavy-chain fragments of Q306-
rFVa incubated with APC. An incubation mixture of Q306-rFVa with APC
as in Fig. 8(C) was subjected to immunoblotting for heavy-chain epitopes
using 125I-secondary antibody and phosphoimaging. Bands were quantitated
relative to the intensity of the heavy chain band without addition of APC
(100%). The relative intensity of a given band can be compared over time
even though the intensity of a band of one mobility can not be compared
directly with the intensity of a band of a different mobility.
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of the 1±306 fragment in Fig. 8 A, B and D, and by comparing
the similar k306s for plasma-derived FVa, wild-type rFVa and
Q506-rFVa. The mutant Q306-rFVa could not be fully inactivated
by APC under conditions where Q506-rFVa was . 90% inac-
tivated, indicating that R306 is the most important APC-cleavage
site for normal FVa inactivation. Proteolytic fragments were
observed due to APC cleavage in Q306-rFVa at R506 and at later
time points, due to probable cleavage at R679. If mutation
occurred at R306 of FV in humans, it might be predicted to cause
more severe thrombophilia than the Arg506Gln mutation. Since
this does not involve a CpG sequence, it may not be a frequent
event. However, reports of the FV mutation Arg306Gly in two
thrombotic and one nonthrombotic Hong Kong Chinese subjects
and the mutation Arg306Thr in one thrombotic patient in
England were published recently [52, 53].
Wei et al. [54] reported that APC cleavage at R306 is not
necessary for inactivation of rFV or rFVa. In contrast, under the
conditions of our studies, our data suggest that cleavage of R306
is necessary for efficient APC inactivation of FVa. However, in
clotting assays, the APC-resistance ratio for unactivated Q306-
rFV in plasma is intermediate between that of normal plasma-
derived or wild-type rFV and FVa, and that of Q306-rFVa, Q506-
rFV or Q506-rFVa (Fig. 6), indicating that the mechanism of
inactivation of Q306-rFV is distinct from that of Q306-rFVa.
Further studies will be needed to elucidate differences in
mechanisms of inactivation of FV vs. FVa [25,36].
The double mutant Q306Q506-rFVa was extremely resistant to
APC, with no significant loss of activity (^ 10%) under all
conditions tested and an APC-resistance ratio of 1.0. No heavy-
chain fragments were observed on immunoblots of Q306Q506-
rFVa incubated with APC. This suggests that either R679
cleavage did not occur in this mutant or that it contributed little
to inactivation. Thus, cleavage either at R306 or at R506 is needed
for any significant inactivation of FVa. However, the biphasic
inactivation curves for Q506-rFVa and Q306-rFVa suggest that
R679 cleavage probably contributes in a minor way to APC inac-
tivation of these molecules, and fragments observed on immuno-
blots suggest that cleavage occurred at R679 in Q306-rFVa and
wild-type rFVa. It is possible that cleavage at 306 or 506 facilitates
cleavage at 679. Nonenzymatic inhibition is not likely to explain
the final phase of inactivation, as an active site mutant of APC
(S360 A) that inhibits FVa without cleaving it [55] has a maxi-
mum effect in seconds, not in the $ 20 min seen here.
Q306Q506-rFV was very resistant to cleavage and activation by
FXa, but not by thrombin. Thus APC cleavage or mutation at
residues 306 and 506 may alter FXa-binding sites in FVa and in
FV, and this supports our other studies demonstrating FXa-
binding sites near these residues [56, 57]. In a three-dimensional
model of the A domains of FVIIIa [58], the residues
homologous to R306 and R506 in FVa are close spatially, and
thus these regions in FVa may form an extended binding site for
FXa. However, the mechanism of poor FXa activation of
Q306Q506-rFV did not appear to involve inability of the double
mutant to bind FXa. Rather, Q306Q506-rFV bound to FXa in a
nonproductive manner in which the ability of FXa to generate
activity from normal FV was inhibited (Fig. 5). The combined
studies of the behavior of Q306Q506-rFV and Q306Q506-rFVa
with FXa raise the interesting question of how the mode of
binding of FXa to FV differs from that of FXa to FVa. Regions
near FV residues 306 and 506 appear to be involved in either
case.
A FXa-binding site and/or a prothrombin-binding site is
possibly altered in Q306Q506-rFVa, because it a has a low
activity-to-antigen ratio when thrombin activated. Since there is
evidence from several of our studies using FVa or APC peptides
[56,57,59±61] that a FXa-binding site(s) overlaps with an APC-
binding site(s), altered binding of APC to the double mutant
could also explain its resistance to R679 cleavage. The protection
of FVa from APC by FXa [62] was shown to be exerted at the
R506 site [26]. If binding sites for FXa and APC exist near both
residues 306 and 506 in FVa, as suggested in our other studies
[56,57,59,61], a double mutation may have a synergistic effect
with respect to the altered binding of FXa and APC. This notion
is further supported by the observation that Q506-FV is strongly
resistant to nonenzymatic inhibition by the active-site mutant of
APC (S360 A) [55], suggesting that binding to APC is altered in
Q506-FV.
It is interesting to note that the specific activity of thrombin-
activated Q306Q506-rFVa was , 50±77% based on comparison
of activity with antigen and was approximately the same as seen
in Q306-rFVa that had been inactivated by APC, i.e. , 60% of
maximum activity after 1 h. Thus, mutation at both sites appears
to produce a FVa molecule about equivalent in activity to a
molecule mutated at the 306 site and cleaved at the 506 site. It is
possible to speculate that FXa binding may be impaired in either
case. Upon titration with FXa, we found an apparent functional
Kd of 35 pm for wild-type rFVa and Q
306-rFVa, in agreement
with Ye and Esmon [63]. After the heavy chain of Q306-rFVa
was . 70% cleaved by APC, the apparent functional Kd
increased to 80 pm, suggesting impairment of FXa-binding sites.
Use of normal FVa, wild-type rFVa and the several R306 and
R506 APC cleavage site rFV mutants allows estimation of
average rate constants for APC cleavages at R506, R306 and R679
in FVa of 55, 9.4 and 0.6 £ 106m21´s21, respectively, which is
in reasonable agreement with other reports [29, 33, 54].
Cleavage at R679 appears to contribute in a minor way to loss
of FVa activity, although this was not proven. Since the APC-
resistance ratio of Q306-rFV differs from that of Q306-rFVa,
these studies also show that the mechanisms for inactivation of
Q306-rFV differ notably from those for Q306-rFVa. FVa cleaved
at R506 and R679 retains , 60% activity while FVa cleaved at
R306 exhibits , 10% activity under the same conditions. Thus,
the most important APC-cleavage site for efficient APC inacti-
vation of FVa is R306. The Q506 mutation in FV may be a
relatively mild risk factor for thrombosis partly because it
creates a deficiency in a rapid but mild anticoagulant mechan-
ism, namely, the conversion of fully active FVa to partially
active FVa cleaved by APC at R506.
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